MedTrace Logo

Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics

NCT06083779 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2023-10-16

No results posted yet for this study

Summary

The purpose of this study is to enable non-invasive early detection of endometrial cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage endometrial cancer patients and healthy individuals will be subjected to whole-genome sequencing. Five different feature types, including Fragment Size Distribution, nucleosome features, SBS Signatures, BreakPoint Motif , and Copy Number Variation will be assessed to generate this model.

Conditions

Interventions

GENETIC

low-depth whole-genome sequencing technology

the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)

Sponsors & Collaborators

  • Nanjing Geneseeq Technology Inc.

    collaborator INDUSTRY

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Bingzhong Zhang, MD · The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-01-31
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083779 on ClinicalTrials.gov